Sergliflozin A is an inhibitor of sodium-glucose cotransporter 2 (SGLT2; Ki = 2.39 nM for the human transporter) and an active metabolite of sergliflozin etabonate.1 It is formed from sergliflozin etabonate by esterases and selectively inhibits SGLT2 over SGLT1 (Ki = 708 nM for the human transporter). Co-infusion of sergliflozin A and glucose reduces maximal renal glucose reabsorption rates in rats.
References:
[1]. Katsuno, K., Fujimori, Y., Takemura, Y., et al.Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose levelJ. Pharmacol. Exp. Ther.320(1)323-330(2007).